ARWR.OQ
Latest Trade
82.07USDChange
2.05(+2.56%)Volume
412,087Today's Range
-
82.2452 Week Range
-
86.59As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 80.02 |
|---|---|
Open | 79.81 |
Volume | 412,087 |
3M AVG Volume | 21.04 |
Today's High | 82.24 |
Today's Low | 79.50 |
52 Week High | 86.59 |
52 Week Low | 19.55 |
Shares Out (MIL) | 102.76 |
Market Cap (MIL) | 8,433.25 |
Forward P/E | -348.34 |
Dividend (Yield %) | -- |
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers Of Alpha-1 Liver Disease
Arrowhead ARO-AAT Phase 2 Interim Results Show Improvements In Key Parameters After 6 Months Of Treatment
Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.13
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Industry
Biotechnology & Drugs
Contact Info
177 E Colorado Blvd, Suite 700
PASADENA, CA
91105
United States
+1.626.6964702
http://arrowheadpharma.com/Executive Leadership
Douglass Bruce Given
Chairman of the Board
Christopher Richard Anzalone
President, Chief Executive Officer, Director
Kenneth Allen Myszkowski
Chief Financial Officer
Curt W. Bradshaw
Chief Scientific Officer
Patrick C. O'Brien
General Counsel
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 95.84 |
Price To Book (MRQ) | 18.19 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -23.00 |
Return on Equity (TTM) | -19.39 |
* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2020 SECOND QUARTER RESULTS
* ARROWHEAD PHARMACEUTICALS ANNOUNCES RETIREMENT OF COO BRUCE GIVEN Source text for Eikon: Further company coverage:
* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2A STUDY OF ARO-ENAC FOR TREATMENT OF CYSTIC FIBROSIS
* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRECAUTIONARY MEASURES TO MITIGATE EFFECTS OF NOVEL CORONAVIRUS (COVID-19) SPREAD
* ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-HSD IN NORMAL HEALTHY VOLUNTEERS AND PATIENTS WITH NASH OR SUSPECTED NASH Source text for Eikon: Further company coverage:
Arrowhead Pharmaceuticals Inc <ARWR.O> said on Thursday Johnson & Johnson <JNJ.N> would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.
Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.
* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE
* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS
* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:
* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE
* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT
* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:
* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS
* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.